MedTrace Logo

Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

NCT07541391 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-30

No results posted yet for this study

Summary

The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe the potential benefits outweigh the risks of this trial.

Conditions

Interventions

BIOLOGICAL

PMCC-COE-KMA

PMCC-COE-KMA is a cellular immunotherapy derived from autologous mononuclear cells that have undergone ex vivo modification to target KMA on the surface of cancer cells. Autologous T-cells are genetically programmed using LV transduction to express a CAR, which comprises an antigen recognition moiety liked to a T-cell receptor signalling domain. This makes the CAR T-cells capable of recognising KMA on tumour cells and triggering target cell destruction in a major histocompatibility complex-independent manner.

Sponsors & Collaborators

  • HaemalogiX Ltd

    collaborator UNKNOWN

  • Peter MacCallum Cancer Centre, Australia

    lead OTHER

Principal Investigators

  • Mark Dowling, MBBS, PhD · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-09-30
Completion
2030-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541391 on ClinicalTrials.gov